NASDAQ:SBBPStrongbridge Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Strongbridge Biopharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.41 -0.01 (-0.29 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$3.31Now: $3.41▼$3.4850-Day Range$1.88MA: $2.79▼$3.7652-Week Range$1.43Now: $3.41▼$3.89Volume166,190 shsAverage Volume409,613 shsMarket Capitalization$184.99 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingStrongbridge Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.88, Strongbridge Biopharma has a potential upside of 189.6% from its current price of $3.41.Amount of Analyst CoverageStrongbridge Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesStrongbridge Biopharma has received 298 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStrongbridge Biopharma has received 363 “underperform” votes. (Add your “underperform” vote.)Community SentimentStrongbridge Biopharma has received 54.92% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote “Outperform” if you believe SBBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStrongbridge Biopharma does not currently pay a dividend.Dividend GrowthStrongbridge Biopharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Strongbridge Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Strongbridge Biopharma is held by insiders.Percentage Held by Institutions47.56% of the stock of Strongbridge Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Strongbridge Biopharma are expected to grow in the coming year, from ($0.76) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Strongbridge Biopharma is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Strongbridge Biopharma is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStrongbridge Biopharma has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SBBP Previous Symbol CUSIPN/A CIK1634432 Webwww.strongbridgebio.com Phone610-254-9200Debt Debt-to-Equity RatioN/A Current Ratio2.86 Quick Ratio2.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.71 million Price / Sales8.52 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book2.56Profitability EPS (Most Recent Fiscal Year)($1.10) Net Income$-49,450,000.00 Net Margins-181.82% Return on Equity-57.46% Return on Assets-36.67%Miscellaneous Employees71 Outstanding Shares54,248,000Market Cap$184.99 million Next Earnings Date7/29/2020 (Estimated) OptionableOptionable NASDAQ:SBBP Rates by TradingView Receive SBBP News and Ratings via Email Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter. Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions How has Strongbridge Biopharma's stock been impacted by COVID-19 (Coronavirus)? Strongbridge Biopharma's stock was trading at $2.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SBBP shares have increased by 47.0% and is now trading at $3.41. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Strongbridge Biopharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Strongbridge Biopharma. When is Strongbridge Biopharma's next earnings date? Strongbridge Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Strongbridge Biopharma. How were Strongbridge Biopharma's earnings last quarter? Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.03. The biotechnology company had revenue of $6.67 million for the quarter, compared to analysts' expectations of $5.97 million. Strongbridge Biopharma had a negative net margin of 181.82% and a negative return on equity of 57.46%. View Strongbridge Biopharma's earnings history. What guidance has Strongbridge Biopharma issued on next quarter's earnings? Strongbridge Biopharma issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, May, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $22-26 million, compared to the consensus revenue estimate of $26.06 million. What price target have analysts set for SBBP? 5 brokers have issued 12-month target prices for Strongbridge Biopharma's shares. Their forecasts range from $6.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $9.88 in the next twelve months. This suggests a possible upside of 189.6% from the stock's current price. View analysts' price targets for Strongbridge Biopharma. Has Strongbridge Biopharma been receiving favorable news coverage? Media coverage about SBBP stock has trended very negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news impact score of -3.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutStrongbridge Biopharma. Who are some of Strongbridge Biopharma's key competitors? Some companies that are related to Strongbridge Biopharma include Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Eagle Pharmaceuticals (EGRX), Kadmon (KDMN), Molecular Templates (MTEM), Dynavax Technologies (DVAX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), G1 Therapeutics (GTHX), Provention Bio (PRVB), Vanda Pharmaceuticals (VNDA), ZIOPHARM Oncology (ZIOP), Homology Medicines (FIXX), Assembly Biosciences (ASMB) and Ardelyx (ARDX). View all competitors. What other stocks do shareholders of Strongbridge Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Viking Therapeutics (VKTX), Genocea Biosciences (GNCA), Opko Health (OPK), Paratek Pharmaceuticals (PRTK), Abeona Therapeutics (ABEO) and Sorrento Therapeutics (SRNE). Who are Strongbridge Biopharma's key executives? Strongbridge Biopharma's management team includes the following people: Mr. John H. Johnson, Exec. Chairman (Age 62, Pay $765.19k)Mr. Robert Matthew Lutz, Chief Financial Officer (Age 51, Pay $543.13k)Mr. Richard S. Kollender CPA, M.B.A., CPA, Chief Operating Officer (Age 51, Pay $50.04k)Dr. Fredric Cohen, Chief Medical Officer (Age 55, Pay $593.89k)Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor What is Strongbridge Biopharma's stock symbol? Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP." Who are Strongbridge Biopharma's major shareholders? Strongbridge Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (6.25%), BlackRock Inc. (3.80%), State Street Corp (1.40%), Geode Capital Management LLC (0.98%), JPMorgan Chase & Co. (0.78%) and Morgan Stanley (0.43%). View institutional ownership trends for Strongbridge Biopharma. Which major investors are selling Strongbridge Biopharma stock? SBBP stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., and UBS Group AG. View insider buying and selling activity for Strongbridge Biopharma. Which major investors are buying Strongbridge Biopharma stock? SBBP stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, JPMorgan Chase & Co., Morgan Stanley, Geode Capital Management LLC, State Street Corp, Two Sigma Investments LP, BlackRock Inc., and Russell Investments Group Ltd.. View insider buying and selling activity for Strongbridge Biopharma. How do I buy shares of Strongbridge Biopharma? Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Strongbridge Biopharma's stock price today? One share of SBBP stock can currently be purchased for approximately $3.41. How big of a company is Strongbridge Biopharma? Strongbridge Biopharma has a market capitalization of $184.99 million and generates $21.71 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 71 workers across the globe. What is Strongbridge Biopharma's official website? The official website for Strongbridge Biopharma is www.strongbridgebio.com. How can I contact Strongbridge Biopharma? Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
